- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Fr | Biogen's higher Spinraza dose shows better efficacy in Phase II/III trial | ||
| Fr | After failed FSGS bid, Travere wins full FDA approval for Filspari in IgAN | ||
| Fr | Investment opportunities in atopic dermatitis may drive innovation | ||
| Fr | Men taking valproate and their partners warned to use contraception by MHRA | ||
| Fr | GSK's asthma blockbuster Nucala secures win in COPD Phase III trial | ||
| Fr | FDA grants ODD to Abdera's neuroendocrine carcinoma treatment | ||
| Fr | NImmune and BioTherapeutics partner on precision medicine development | ||
| Fr | Evotec partners X-Chem for tech-enabled drug discovery | ||
| Fr | FDA approves Amneal and Shilpa's oncology product BORUZU | ||
| Do | ESC 2024: New PACMAN-AMI trial analysis sheds insights on Praluent efficacy | ||
| Do | Lilly partners with Haya for lncRNA obesity target deal worth $1bn | ||
| Do | Moderna mpox mRNA vaccine shows early promise in monkey study | ||
| Do | eGenesis scoops $191m for genetically modified pig kidney transplant trial | ||
| Do | IN8bio cuts staff and pipeline to focus on AML cell therapy | ||
| Do | NHS England offers MSD belzutifan for von Hippel-Lindau disease | ||
| Do | UK bans xylazine and 21 other substances to fight drug abuse | ||
| Do | ArsenalBio secures $325m to develop cell therapy programmes | ||
| Do | Lilly and EVA Pharma to expand baricitinib access in Africa | ||
| Mi | Combating Pharmaceutical Crime with On-Dose Authentication | ||
| Mi | ProKidney drops Phase III CKD study to focus on US market and save up to $175m | ||
| Mi | How to optimize efficiencies at site-centric clinical trials | ||
| Mi | A quick guide to transferring a commercial drug product to a new fill-finish CDMO | ||
| Mi | Acepodia collaborates with Pfizer to advance antibody-cell conjugation therapies | ||
| Mi | Athira's stock topples after Alzheimer's drug flops in Phase II/III trial | ||
| Mi | Actimed's ALS candidate wins FDA orphan drug designation |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
